中文名 | SD-06 |
英文名 | SD-06 |
别名 | SD-06-1游离 3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑 3-[N-(2-羟基乙酰基)-4-哌啶基]-4-(4-嘧啶基)-5-(4-氯苯基)吡唑 1级 1-(4-(5-(4-氯苯基)-4-(嘧啶-4-基)-1H-吡唑-3-基)哌啶-1-基)-2-羟基乙酮 |
英文别名 | SD06 SD-06 SD 06 CS-2591 ATG-010 SD 0006 SD-06-1 SD 0006(SD-06) 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole 1-(4-(5-(4-Chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-2-hydroxyethanone |
CAS | 271576-80-8 |
化学式 | C20H20ClN5O2 |
分子量 | 397.86 |
密度 | 1.367 |
沸点 | 652.6±55.0 °C(Predicted) |
溶解度 | DMSO: ≥ 29 mg/mL |
酸度系数 | 9.39±0.50(Predicted) |
存储条件 | 2-8°C |
体外研究 | SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate. |
体内研究 | SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy. SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling. Animal Model: 8- to 12-week-old DBA/1 mice. Dosage: 3.75, 7.5 and 15 mg/kg. Administration: Orally twice daily. Result: Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.513 ml | 12.567 ml | 25.135 ml |
5 mM | 0.503 ml | 2.513 ml | 5.027 ml |
10 mM | 0.251 ml | 1.257 ml | 2.513 ml |
5 mM | 0.05 ml | 0.251 ml | 0.503 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!